Mirum Pharmaceuticals, Inc. - common stock (MIRM): Price and Financial Metrics

Mirum Pharmaceuticals, Inc. - common stock (MIRM): $27.81

0.41 (-1.45%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

MIRM Price/Volume Stats

Current price $27.81 52-week high $35.56
Prev. close $28.22 52-week low $20.81
Day low $27.71 Volume 224,000
Day high $28.41 Avg. volume 604,905
50-day MA $28.58 Dividend yield N/A
200-day MA $28.25 Market Cap 1.30B

MIRM Stock Price Chart Interactive Chart >

MIRM POWR Grades

  • Growth is the dimension where MIRM ranks best; there it ranks ahead of 79.84% of US stocks.
  • MIRM's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
  • MIRM ranks lowest in Stability; there it ranks in the 4th percentile.

MIRM Stock Summary

  • With a year-over-year growth in debt of 119.82%, MIRUM PHARMACEUTICALS INC's debt growth rate surpasses 92.83% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, MIRUM PHARMACEUTICALS INC is reporting a growth rate of 348.84%; that's higher than 96.65% of US stocks.
  • As for revenue growth, note that MIRM's revenue has grown 176.75% over the past 12 months; that beats the revenue growth of 97.12% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to MIRUM PHARMACEUTICALS INC, a group of peers worth examining would be OMIC, ACVA, CERS, ADTN, and NHWK.
  • Visit MIRM's SEC page to see the company's official filings. To visit the company's web site, go to mirumpharma.com.

MIRM Valuation Summary

  • MIRM's price/sales ratio is 9.5; this is 331.82% higher than that of the median Healthcare stock.
  • Over the past 54 months, MIRM's EV/EBIT ratio has gone down 2.5.

Below are key valuation metrics over time for MIRM.

Stock Date P/S P/B P/E EV/EBIT
MIRM 2023-12-29 9.5 5.1 -8.4 -9.4
MIRM 2023-12-28 9.6 5.2 -8.5 -9.5
MIRM 2023-12-27 9.7 5.2 -8.5 -9.5
MIRM 2023-12-26 9.7 5.2 -8.6 -9.6
MIRM 2023-12-22 9.7 5.2 -8.5 -9.5
MIRM 2023-12-21 10.0 5.4 -8.8 -9.9

MIRM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MIRM has a Quality Grade of C, ranking ahead of 49.16% of graded US stocks.
  • MIRM's asset turnover comes in at 0.052 -- ranking 319th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows MIRM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.052 1 -0.949
2021-03-31 0.000 NA -1.229
2020-12-31 0.000 NA -1.146
2020-09-30 0.000 NA -0.934
2020-06-30 0.000 NA -0.781
2020-03-31 0.000 NA -0.694

MIRM Price Target

For more insight on analysts targets of MIRM, see our MIRM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.33 Average Broker Recommendation 1.29 (Strong Buy)

Mirum Pharmaceuticals, Inc. - common stock (MIRM) Company Bio


Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.


MIRM Latest News Stream


Event/Time News Detail
Loading, please wait...

MIRM Latest Social Stream


Loading social stream, please wait...

View Full MIRM Social Stream

Latest MIRM News From Around the Web

Below are the latest news stories about MIRUM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MIRM as an investment opportunity.

Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia

FOSTER CITY, Calif., December 18, 2023--Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia

Yahoo | December 18, 2023

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., December 09, 2023--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo | December 9, 2023

Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management

Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact on patients, particularly those suffering from Primary Biliary Cholangitis (PBC), an autoimmune liver disease. ...

Yahoo | November 30, 2023

Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference

FOSTER CITY, Calif., November 20, 2023--Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference

Yahoo | November 20, 2023

Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

FOSTER CITY, Calif., November 13, 2023--Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

Yahoo | November 13, 2023

Read More 'MIRM' Stories Here

MIRM Price Returns

1-mo 6.27%
3-mo -11.24%
6-mo 5.22%
1-year 20.81%
3-year 51.47%
5-year N/A
YTD -5.79%
2023 51.38%
2022 22.26%
2021 -8.65%
2020 -28.79%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!